Trial Profile
Open Label Phase 2 Single Agent Study of LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2023
Price :
$35
*
At a glance
- Drugs LCL 161 (Primary)
- Indications Myelofibrosis; Polycythaemia vera; Thrombocytosis
- Focus Therapeutic Use
- 27 May 2022 Status changed from active, no longer recruiting to completed.
- 08 Nov 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2023.
- 08 Nov 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2022.